Table 5.
Immunogenicity of the F1 and rV antibodies (Chu et al., 2016; Hu et al., 2018).
| 15 mcg |
30 mcg |
|||||
|---|---|---|---|---|---|---|
| GMT (95%CI) | Seroconversion rate | GMFI (95% CI) | GMT (95%CI) | Seroconversion rate | GMFI (95% CI) | |
| F1 antibody | ||||||
| Baseline | 1.03 (0.99–1.07) | NA | NA | 1.00 (1.00–1.00) | NA | NA |
| Day 28 | 13.88 (10.21–18.87) | 78.99% | 13.48 (9.97–18.24) | 22.10 (16.31–29.91) | 84.03% | 22.10 (16.32–29.91) |
| Day 56 | 47.55 (36.29–62.31) | 93.28% | 46.19 (35.24–60.52) | 90.53 (72.33–113.31) | 96.64% | 90.53 (72.33–113.31) |
| Month 6 | 165.31 (134.00–196.60) | 100% | NR | 270.33 (219.50–321.20) | 100% | NR |
| Month 12 | 140.10 (93.94–186.30) | 99.16% | NR | 198.80 (152.30–245.20) | 100% | NR |
| rV IgG antibody | ||||||
| Baseline | 11.07 (10.25–11.97) | NA | NA | 10.66 (10.05–11.31) | NA | NA |
| Day 28 | 395.81 (278.12–563.30) | 54.62% | 35.74 (25.36–50.38) | 551.71 (406.51–748.76) | 71.43% | 51.75 (38.12–70.25) |
| Day 56 | 2457.70 (2070.06–2917.93) | 99.16% | 221.94 (186.31–264.38) | 2761.40 (2332.76–3268.79) | 99.16% | 259.00 (218.94–306.39) |
| Month 6 | 452.50 (325.80–579.20) | 42.02% | NR | 728.50 (358.10–1099.00) | 49.15% | NR |
| Month 12 | 225.60 (123.30–347.90) | 16.81% | NR | 323.50 (204.90–442.10) | 27.12% | NR |
CI = confidence interval; F1 = faction 1; GMFI = geometric mean fold increase; GMT = geometric mean titre; IgG = immunoglobulin G; NR = not reported; rV = recombinant virulence.